Pull to refresh
Logo
Daily Brief
Following
Why Ranks Sign Up
Adrian Krainer

Adrian Krainer

Co-founder, Stoke Therapeutics; Professor, Cold Spring Harbor Laboratory

Appears in 1 story

Stories

First treatment targeting the genetic root of Dravet syndrome shows dramatic seizure reduction

New Capabilities

Co-founder of Stoke Therapeutics and scientific architect of the TANGO platform

Dravet syndrome is a severe genetic epilepsy that causes hundreds of seizures per month, cognitive decline, and a 15–20 percent mortality rate. For nearly five decades, no treatment addressed the underlying cause — including two drugs approved in the past eight years, which could only partially suppress symptoms.

Updated May 30